- Home
- NVCR vs BCRX Comparison
NVCR vs BCRX Comparison
Compare NVCR & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCR | BCRX |
|---|---|---|
| Founded | 2000 | 1986 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2015 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NVCR | BCRX |
|---|---|---|
| Price | $11.36 | $7.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $27.75 | $20.82 |
| AVG Volume (30 Days) | 2.2M | ★ 3.6M |
| Earning Date | 04-03-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 63.56 |
| EPS | N/A | ★ 0.08 |
| Revenue | ★ $605,220,000.00 | $25,186,000.00 |
| Revenue This Year | $10.50 | $40.21 |
| Revenue Next Year | $4.02 | $6.06 |
| P/E Ratio | ★ N/A | $93.38 |
| Revenue Growth | ★ 18.82 | N/A |
| 52 Week Low | $9.82 | $6.00 |
| 52 Week High | $22.29 | $11.31 |
Technical Indicators
Market Signals| Indicator | NVCR | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 62.44 |
| Support Level | $10.69 | $6.26 |
| Resistance Level | $11.47 | $6.91 |
| Average True Range (ATR) | 0.90 | 0.26 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 26.50 | 93.60 |
Price Performance
Historical ComparisonAbout NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.